ArticleFrontiers in pharmacology2026
Factors affecting trough concentrations of voriconazole: a dual-center retrospective analysis focusing on loading dose and inflammatory state effects.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are significant interindividual variations in voriconazole (VCZ) blood concentrations, which affect both treatment efficacy and safety. Objective: Our goal is to identify the factors influencing VCZ trough concentrations and provide new evidence for individualized dosing. Methods: A total of 281 hospitalized patients receiving VCZ were enrolled. Demographic, liver and kidney function, C-reactive protein (CRP) and other clinical data were collected. Trough concentrations were determined using HPLC. Multivariate linear regression and ordinal logistic regression were employed to identify influencing factors, with predictive performance assessed by ROC curves. Results: CRP is a significant positive predictor of VCZ trough concentration (B = 0.010, Conclusion: The high variability in VCZ trough concentrations may be partially attributed to factors such as weight, loading dose, liver function, inflammation and concomitant medications. Although loading doses enable rapid efficacy, they increase the risk of supratherapeutic concentrations. Patients in the high-CRP group are more likely to exceed 5.0 μg/mL, demonstrating the best discriminative ability for predicting excessively high concentrations. These findings provide new evidence for VCZ dose optimization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.